FEATURED EDITORIAL
Digital healthcare and AI technologies play a crucial role in exploring and treating a range of rare diseases as we welcome a new era of personalized care and potentially better patient outcomes.
- 8 Key Takeaways Of The Proposed FDA Modernization Act 3.0
- FDA’s Updated Guidance On Human Genome Editing: New Implications & Remaining Questions
- AI's Role In Advancing Rare Disease Research
- FDA’s CBER Issues Final Guidance For CAR T Cell Products
- PROTACs And Molecular Glues: Rethinking What Is Possible
- 2024 And Beyond: The State Of Alzheimer's Disease Research And Drug Development
- Indo-U.S. Collaboration Can Accelerate Drug Discovery — Here’s How
FEATURED APPLICATION CONTENT
-
This study demonstrates the automated magnetic isolation of CD4/CD8+ cells from fresh or frozen leukapheresis using a functionally closed cell processing system paired with a modular application.
-
Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.
-
Discover how an Organ-Chip can be used to create a comprehensive recapitulation of the proximal tubule, addressing the need for more human-relevant preclinical models in the pharmaceutical industry.
-
Discover an Intestine-Chip that integrates the robust cell sourcing of organoids with Organs-on-Chips technology to overcome experimental limitations and yield a closer-to-human transcriptomic profile.
-
There is a growing need for more human-relevant preclinical models. Explore how Organ-Chips offer a viable solution and can be used to create a comprehensive recapitulation of the liver sinusoid.
-
Learn about the development and characterization of Organ-Chips and what makes them the most comprehensive model of the colonic epithelial-endothelial interface that is commercially available.
-
Organ-on-a-Chip technology has emerged as a solution to the limitations of conventional preclinical models. Learn how Liver-Chips can be used to test the delivery efficiency and safety of AAV vectors.
-
Traditional models for studying inflammatory bowel disease (IBD) often fall short. See how the Colon Intestine-Chip was used to model the progression of IBD driven by immune cells more completely.
-
Here, we review how an advanced in vitro model closely aligned with the human duodenum was utilized to evaluate the toxicity of indomethacin, a known gastrointestinal toxicant.
-
Learn about a novel preclinical model and how it enables the study of cytokine-mediated barrier inflammation mechanisms as well as the efficacy of anti-inflammatory therapeutics.
-
An evaluation of 150 drug candidates causing adverse events in humans revealed testing in rats and dogs predicted only 71% of toxicities in humans. Discover a solution to this translational challenge.
-
Here, we analyze the throughput performance of sterilizing grade filters across moderate-to-high concentrations of mAbs and immunoglobulins and demonstrate how filter selection can impact your process.
FEATURED NEWS HEADLINES
- Synthekine Announces U.S. FDA Clearance Of IND Application For CD19 CAR-T And Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, For Treatment Of Lupus Without Lymphodepletion
- CinFina Pharma Announces FDA Clearance Of Investigational New Drug Application And First Participants Dosed In Phase 1 Trial Of CIN-110 For The Treatment Of Obesity
- Researchers Devise New Method To Find Proteins For Targeted Treatment Of Disease
- EPNextS Group And Frontage Laboratories, Inc. Announce Collaboration In Early Phase Clinical Trials In The United States To Improve ‘Drug Lag’ And ‘Drug Loss’ Issues In Japan
- Teva UK And Closed Loop Medicine Announce Strategic Partnership To Advance Development Of Personalised Medicines
- Ubiquigent And Debiopharm Enter Agreement To Support USP1 Inhibitor Programme For Debio 0432
- Safer, More Efficient Drug Discovery
- Amneal Receives U.S. FDA Approval For Ciprofloxacin And Dexamethasone Otic Suspension
- Biocytogen Enters Collaboration With ABL Bio To Develop New Bispecific Antibody-Drug Conjugates
- Bio-Thera Solutions Receives IND Clearance From US FDA To Initiate A Phase II Study For BAT8006, An Innovative Antibody Drug Conjugate Targeting Folate Receptor α
ARCHIVED NEWSLETTER
- 03.26.24 -- Indo-U.S. Collaboration Can Accelerate Drug Discovery — Here's How
- 03.19.24 -- Understanding Undruggable Targets: Challenges And Progress
- 03.18.24 -- Regulatory & GMP Manufacturing Insights Into mRNA-LNP Drug Products
- 03.13.24 -- Achieving Efficient Process Development And Validation
- 03.12.24 -- The Benefits Of Using GenAI In Drug Discovery And Preclinical Development